Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.44 |
| ▸ | TOP1 | P11387 | 3/20 | 0.38 |
| ▸ | CYCS | P99999 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677253 | 1.00 | TERT (0.44) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL4138914 | 0.98 | TERT (0.43) | TERTTOP1CYCSENPP2 | |
| Bromide SCHEMBL4128664 | 0.98 | TERT (0.43) | TERTTOP1CYCSENPP2 | |
| SCHEMBL30417480 | 0.98 | TERT (0.43) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL30474599 | 0.98 | TERT (0.43) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL7246124 | 0.98 | TERT (0.43) | TERTTOP1CYCSENPP2 | |
| SCHEMBL4126389 | 0.94 | TERT (0.40) | TERTTOP1CYCSENPP2 | |
| Acetic Acid SCHEMBL9073655 | 0.92 | TOP1 (0.44) | TERTTOP1CYCSENPP2 | |
| SCHEMBL2535689 | 0.91 | TERT (0.47) | TERTTOP1CYCSENPP2 | |
| SCHEMBL9438544 | 0.91 | TERT (0.47) | TERTTOP1CYCSENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288653-A1 | ARTIFICIAL BLOOD SUBSTITUTES | CHANG THOMAS MING SWI (CA) | 2025-09-18 | — | — | US | claimed |
| US-20160228356-A1 | THE CONTINUOUS LONG-TERM CONTROLLED RELEASE OF TELOMERASE INHIBITORS | LASTER, Brenda (IL) | 2016-08-11 | — | — | US | claimed |
| WO-2015040622-A1 | THE CONTINUOUS LONG-TERM CONTROLLED RELEASE OF TELOMERASE INHIBITORS | LASTER BRENDA (IL) | 2015-03-26 | — | — | WO | claimed |
| US-8501366-B1 | Nanoengineered membrane electrode assembly interface | SANDIA CORPORATION (US) | 2013-08-06 | — | — | US | claimed |
| US-20120142623-A1 | Compositions And Methods For Predicting Inhibitors Of Protein Targets | UNIVERSITY OF WASHINGTON | 2012-06-07 | — | — | US | claimed |
| EP-1401379-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2008006085-A2 | COMPOSITIONS AND METHODS FOR PREDICTING INHIBITORS OF PROTEIN TARGETS | UNIVERSITY OF WASHINGTON (US) | 2008-01-10 | — | — | WO | claimed |
| US-20070248534-A1 | Auger effect-based cancer therapy method | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2007-10-25 | — | — | US | claimed |
| US-20050112058-A1 | Auger effect-based cancer therapy method | BEN-GURION UNIVERSITY OF THE NEGEV (IL) | 2005-05-26 | — | — | US | claimed |
| WO-2004061416-A2 | METHODS FOR ATTACHING MOLECULES | GENORX, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| US-5702804-A | Recording sheets | XEROX CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5541633-A | Ink jet printing of concealed images on carbonless paper | XEROX CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5286286-A | Containing diethylene glycol monobutyl ether, glycerol, and a dansyl or porphyrin chromophores | XEROX CORPORATION (US) | 1994-02-15 | — | — | US | claimed |
| US-5271764-A | Ink compositions | XEROX CORPORATION (US) | 1993-12-21 | — | — | US | claimed |
| US-5256193-A | Porphyrin chromophore and dendrimer ink composition | XEROX CORPORATION (US) | 1993-10-26 | — | — | US | claimed |
| US-4986256-A | MAGNETIC RESONANCE IMAGING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1991-01-22 | — | — | US | claimed |
| WO-1989011277-A2 | PORPHYRIN AND PHTHALOCYANINE ANTIVIRAL COMPOSITIONS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-11-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228356-A1 | THE CONTINUOUS LONG-TERM CONTROLLED RELEASE OF TELOMERASE INHIBITORS | TERT, POT1, TERF2 | TERT 1/4885TOP1 1486/4885CYCS 842/4885 |
| US-20050112058-A1 | Auger effect-based cancer therapy method | LIG4, DNMT1, UNG | TERT 1097/4885TOP1 36/4885CYCS 2086/4885 |
| US-20070248534-A1 | Auger effect-based cancer therapy method | LIG4, DNMT1, UNG | TERT 1097/4885TOP1 36/4885CYCS 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.